tradingkey.logo

Gilead falls as CVS holds off coverage for its HIV prevention drug

ReutersAug 21, 2025 12:05 PM

Shares of biopharmaceutical company Gilead Sciences GILD.O fall 2.9% to $115.34 in premarket

Reuters reports CVS Health CVS.N to not add Gilead's new HIV prevention drug Yeztugo to its commercial plans for now

CVS cites clinical, financial, and regulatory reasons for decision, a spokesperson told Reuters

Adds, won't cover Yeztugo under its Affordable Care Act formularies, which follow U.S. Department of Health and Human Services (HHS) recommendations

Gilead still negotiating with CVS over Yeztugo; U.S. list price more than $28,000/year

Co aims for 75% U.S. insurer coverage by year-end and 90% by June 2026

A majority of brokerages rate the stock "buy" or higher; their median PT is $128

Up to last close, stock had risen over 28.5% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI